(Q43765361)

English

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

Michael Hutchinson

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

object named as

Eva Havrdova

1

0 references

2

object named as

Steven Galetta

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Gavin Giovannoni

8

object named as

Gavin Giovannoni

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Dusan Stefoski

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

David Bates

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Chris H Polman

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Paul W O'Connor

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

J Theodore Phillips

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Fred D Lublin

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Amy Pace

11

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Richard Kim

12

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Robert Hyde

13

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

7 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

254-260

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970021-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(09)70021-3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43765361&oldid=2103143884"